The use of classic hallucinogens/psychedelics in a therapeutic context: healthcare policy opportunities and challenges (2021)
- Authors:
- USP affiliated authors: SANTOS, RAFAEL GUIMARÃES DOS - FMRP ; HALLAK, JAIME EDUARDO CECILIO - FMRP ; ROCHA, JULIANA MENDES - FMRP ; ROSSI, GIORDANO NOVAK - FMRP
- Unidade: FMRP
- DOI: 10.2147/RMHP.S300656
- Subjects: ALUCINOGÊNICOS; RECEPTORES DE DROGA; COGNIÇÃO; HUMOR; POLÍTICAS PÚBLICAS
- Keywords: Hallucinogens; Healthcare; Psychedelics
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Publisher place: Macclesfield
- Date published: 2021
- Source:
- Título: Risk Management and Healthcare Policy
- ISSN: 1179-1594
- Volume/Número/Paginação/Ano: v. 14, p. 901-910, 2021
- Status:
- Artigo publicado em periódico de acesso aberto (Gold Open Access)
- Versão do Documento:
- Versão publicada (Published version)
- Acessar versão aberta:
-
ABNT
SANTOS, Rafael Guimarães dos et al. The use of classic hallucinogens/psychedelics in a therapeutic context: healthcare policy opportunities and challenges. Risk Management and Healthcare Policy, v. 14, p. 901-910, 2021Tradução . . Disponível em: https://doi.org/10.2147/RMHP.S300656. Acesso em: 01 abr. 2026. -
APA
Santos, R. G. dos, Bouso, J. C., Rocha, J. M., Rossi, G. N., & Hallak, J. E. C. (2021). The use of classic hallucinogens/psychedelics in a therapeutic context: healthcare policy opportunities and challenges. Risk Management and Healthcare Policy, 14, 901-910. doi:10.2147/RMHP.S300656 -
NLM
Santos RG dos, Bouso JC, Rocha JM, Rossi GN, Hallak JEC. The use of classic hallucinogens/psychedelics in a therapeutic context: healthcare policy opportunities and challenges [Internet]. Risk Management and Healthcare Policy. 2021 ; 14 901-910.[citado 2026 abr. 01 ] Available from: https://doi.org/10.2147/RMHP.S300656 -
Vancouver
Santos RG dos, Bouso JC, Rocha JM, Rossi GN, Hallak JEC. The use of classic hallucinogens/psychedelics in a therapeutic context: healthcare policy opportunities and challenges [Internet]. Risk Management and Healthcare Policy. 2021 ; 14 901-910.[citado 2026 abr. 01 ] Available from: https://doi.org/10.2147/RMHP.S300656 - Cross-sectional associations between lifetime use of psychedelic drugs and psychometric measures during the COVID-19 confinement: a transcultural study
- Longitudinal and transcultural assessment of the relationship between hallucinogens, well-being, and post-traumatic growth during the COVID-19 pandemic
- Tripping to cope: coping strategies and use of hallucinogens during the COVID-19 pandemic in three cultural contexts
- The adverse events of ibogaine in humans: an updated systematic review of the literature (2015–2020)
- Can hallucinogens alter personality functioning?: results of a clinical trial involving the Pfister’s Colors Pyramids test
- Adverse effects after Ayahuasca administration in the clinical setting [Carta]
- Main targets of ibogaine and noribogaine associated with its putative anti-addictive effects: a mechanistic overview
- The effects of ketamine and classic hallucinogens on neurotrophic and inflammatory markers in unipolar treatment-resistant depression: a systematic review of clinical trials
- Safety issues of psilocybin and LSD as potential rapid acting antidepressants and potential challenges
- Classical hallucinogens as antidepressant drugs [Editorial]: a cautionary approach
Informações sobre a disponibilidade de versões do artigo em acesso aberto coletadas automaticamente via oaDOI API (Unpaywall).
Por se tratar de integração com serviço externo, podem existir diferentes versões do trabalho (como preprints ou postprints), que podem diferir da versão publicada.
Download do texto completo
| Tipo | Nome | Link | |
|---|---|---|---|
 |
003219349.pdf | Direct link |
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
